A5100414332- CAR-T cell therapy research
- Cancer Immunotherapy and Biomarkers
- Immune Cell Function and Interaction
- Monoclonal and Polyclonal Antibodies Research
- Immunotherapy and Immune Responses
- Lymphoma Diagnosis and Treatment
- Viral Infectious Diseases and Gene Expression in Insects
- Lung Cancer Research Studies
- Head and Neck Cancer Studies
- Virus-based gene therapy research
- Neuroendocrine Tumor Research Advances
- Effects of Radiation Exposure
- Synthesis and Biological Evaluation
- Peptidase Inhibition and Analysis
- Nanowire Synthesis and Applications
- Advancements in Semiconductor Devices and Circuit Design
- CRISPR and Genetic Engineering
- Immune cells in cancer
- DNA Repair Mechanisms
- Lung Cancer Treatments and Mutations
- Cancer-related molecular mechanisms research
- Hematopoietic Stem Cell Transplantation
- PI3K/AKT/mTOR signaling in cancer
- Apelin-related biomedical research
- Cancer Mechanisms and Therapy
Fudan University Shanghai Cancer Center
2024-2025
Fujian Medical University
2023-2025
Wuhan University
2024
Renmin Hospital of Wuhan University
2024
Third Xiangya Hospital
2022-2024
Central South University
2022-2024
Union Hospital
2024
Huazhong University of Science and Technology
2024
Mayo Clinic in Arizona
2021-2024
Shandong First Medical University
2023
Heterochromatin in aging stem cells Analysis of human syndromes, such as Werner syndrome (WS), may lead to greater understanding both premature and normal aging. Zhang et al. generated isogenic WS-specific embryonic cell lines (see the Perspective by Brunauer Kennedy). WS-mesenchymal displayed features characteristic aging, including heterochromatin disorganization. WRN protein thus functions maintenance heterochromatin, alterations represent a driving force Science , this issue p. 1160 ;...
Abstract PTEN is a tumour suppressor frequently mutated in many types of cancers. Here we show that targeted disruption leads to neoplastic transformation human neural stem cells (NSCs), but not mesenchymal cells. PTEN-deficient NSCs display neoplasm-associated metabolic and gene expression profiles generate intracranial tumours immunodeficient mice. localized the nucleus NSCs, binds PAX7 promoter through association with cAMP responsive element binding protein 1 (CREB)/CREB (CBP) inhibits...
Although immune checkpoint inhibitors have resulted in durable clinical benefits a subset of patients with advanced cancer, some who did not respond to initial anti-PD-1 therapy been found benefit from the addition salvage chemotherapy. However, mechanism responsible for successful chemoimmunotherapy is completely understood. Here we show that circulating CD8+ T cells expressing chemokine receptor CX3CR1 are able withstand toxicity chemotherapy and increased metastatic melanoma responded...
B7-H3, also referred to as CD276, is a member of the B7 family immune regulatory proteins. B7-H3 overexpressed on many solid cancers, including prostate cancer, renal cell carcinoma, melanoma, squamous carcinoma head and neck, non-small lung breast cancer. Overexpression associated with disease severity, risk recurrence reduced survival. In this article, we report preclinical development MGC018, an antibody-drug conjugate targeted against B7-H3. MGC018 comprised cleavable linker-duocarmycin...
Abstract T cell rejuvenation by PD-1/PD-L1 blockade, despite emerging as a highly promising therapy for advanced cancers, is only beneficial minority of treated patients. There evidence that lack efficient activation may be responsible the failure. Here, we demonstrate IL-21 can targeted to tumor-reactive cells fusion anti-PD-1 antibody. To our surprise, protein PD-1Ab21 promotes generation memory stem (T SCM ) with enhanced proliferation. treatment show potent antitumor effects in...
Triple-negative breast cancer (TNBC) is an aggressive subtype for which effective therapies are lacking.Epidermal growth factor receptor (EGFR) overexpressed in various types of TNBC cells, and several EGFR-specific immunotherapies have been used to treat patients.Chimeric antigen engineered T (CAR-T) cells also as therapies.In this study, we generated two CAR-modified using lentiviral vectors with DNA sequences encoding the scFv regions anti-EGFR antibodies.The cytotoxic antitumor effects...
Abstract Objectives Traditional cancer therapy and regular immunotherapy are ineffective for treating triple‐negative breast (TNBC) patients. Recently, chimeric antigen receptor‐engineered natural killer cells (CAR NK) have been applied to target several hormone receptors on different improve the efficacy of immunotherapy. Furthermore, epidermal growth factor receptor (EGFR) is a potential therapeutic TNBC. Here, we demonstrated that EGFR‐specific CAR NK (EGFR‐CAR cells) could be potentially...
Semaphorin-4A (Sema4A) has been implicated in the co-stimulation of T cells and drives Th1 immune responses by binding to receptor T-cell immunoglobulin mucin domain protein 2 (Tim-2) mice. Here we show that human, but not murine, Sema4A is preferentially expressed on antigen-presenting cells, co-stimulates CD4+ proliferation Th2 responses. By employing two independent cloning strategies, demonstrate Immunoglobulin-like transcript 4 (ILT-4) a for human SEMA4A (hSEMA4A) activated cells. We...
Abstract Cytotoxic CD8+ T cells (CTL) are a crucial component of the immune system notable for their ability to eliminate rapidly proliferating malignant cells. However, T-cell intrinsic factors required human CTLs accomplish highly efficient antitumor cytotoxicity not well defined. By evaluating from responders versus nonresponders treatment with checkpoint inhibitors, we sought identify key associated effective CTL function. Single-cell RNA-sequencing analysis peripheral patients treated...
In spite of impressive success in treating hematologic malignancies, adoptive therapy with chimeric antigen receptor modified T cells (CAR T) has not yet been effective solid tumors, where identification suitable tumor-specific antigens remains a major obstacle for CAR T-cell due to the “on target off tumor” toxicity. Protein tyrosine kinase 7 (PTK7) is member Wnt-related pseudokinases and identified as highly expressed enriched cancer stem (CSCs) from multiple including but limited...
PURPOSE Chronoradiobiology has emerged as a potential field of study with therapeutic implications for cancer treatment. We aimed to investigate the association between radiation chronotherapy and efficacy toxicity patients nasopharyngeal carcinoma (NPC). PATIENTS AND METHODS Patients nonmetastatic NPC treated intensity-modulated radiotherapy in Fujian Cancer Hospital January 2017 December 2019 were included. Propensity score matching (PSM) 1:1:1 was used account selection bias. Cox...
Patients with central nervous system (CNS) lymphomas have a poor prognosis. Chimeric antigen receptor-modified (CAR) T cells shown remarkable efficacy for B-cell non-Hodgkin's lymphoma. However, few studies reported the effects of CAR in treatment CNS lymphoma, and duration remission is short. In this study, seven lymphoma patients (six secondary one patient primary lymphoma) were treated CD19 or CD20 cell therapy, clinical toxicity profiles evaluated. All responded to therapy. Four achieved...
Chimeric antigen receptor-T (CAR-T) cell therapy has made remarkable strides in treating hematological malignancies. However, the widespread adoption of CAR-T is hindered by several challenges. These include concerns about long-term and complex manufacturing process, as well efficacy factors such tumor escape, exhaustion, immunosuppressive microenvironment. Additionally, safety issues like risk secondary cancers post-treatment, on-target off-tumor toxicity, immune effector responses...
Abstract Chimeric antigen receptor‐ (CAR‐)modified T cells have been successfully used to treat blood cancer. With the improved research on anti‐tumour adoptive cell therapy, researchers focused immune other than lymphocytes. Natural killer (NK) received widespread attention as barriers natural immunity. Compared lymphocyte‐related use of NK tumours does not cause graft‐versus‐host disease, significantly improving Moreover, more sources cells, and related modified are less expensive....
Hematological toxicity (hematotoxicity) leading to peripheral cytopenias is a common long-term adverse effect following the use of CD19-chimeric antigen receptor (CD19-CAR) T-cell therapies. However, management remains unclear for patients whose persist beyond 1 month after CAR infusion. We present case 21-year old who received CD19-CAR therapy relapse haploidentical transplant. He developed hematotoxicity and consequently multiple life-threatening infections. administered CD34+...
The prognosis of nasopharyngeal carcinoma (NPC) has been recognized to improve immensely owing radiotherapy combined with chemotherapy. However, patients metastatic NPC have a poor prognosis. Immunotherapy dramatically prolonged the survival NPC. Hence, further research on immune-related biomarkers is imperative establish NPC.10 RNA expression profiles were generated from or without distant metastasis after chemoradiotherapy Fujian Cancer Hospital. differential genes identified and validated...
Patients with advanced cancers who either do not experience initial response to or progress while on immune checkpoint inhibitors (ICIs) receive salvage radiotherapy reduce tumor burden and tumor-related symptoms. Occasionally, some patients substantial global regression a rebound of cytotoxic CD8
Abstract Background: Although CAR T-cell therapy has achieved remarkable response rates in adult patients (pts) with relapsed and refractory B-cell non-Hodgkin’s lymphoma (NHL), 20-30% of pts still have primary disease, 30-40% relapse, often within 6 months therapy. Given that durable clinical can be without T cell persistence, we hypothesized remission is correlated the expansion tumor-reactive receptor (TCR) clones following infusion. To assess this, examined TCR repertoire B-NHL who...
The role of chronoradiobiology in nasopharyngeal carcinoma (NPC) has not been fully elucidated. We sought to investigate the impact radiotherapy rhythm on survival outcomes individuals explore a chronomodulated radiation strategy improve prognosis NPC.
Abstract Introduction: B7-H3, a member of the B7 family immunomodulatory molecules, is overexpressed in wide range solid tumors. B7-H3 tumor overexpression has been correlated with disease severity and poor outcome. MGC018 duocarmycin-based antibody-drug conjugate (ADC) targeting B7-H3. exhibits favorable preclinical profile, strong reactivity toward cells tumor-associated vasculature, limited normal tissue reactivity, potent antitumor activity B7-H3-expressing xenografts. With emergence...
Abstract Background Although CAR T-cell therapy has achieved remarkable response in patients (pts) with B-cell non-Hodgkin’s lymphoma (NHL), 20-30% of pts still have primary refractory disease (PD1), and another 30-40% relapse (PD2). We others shown that monocytes can modulate functions impact clinical to chemoimmunotherapy NHL. Given nadir recovery kinetics differ from lymphocytes post lymphodepletion chemotherapy, we hypothesize monocyte phenotype at peak CAR-T expansion the early month...